Abstract
Alternative genetic pathways characterized by specific genetic profiles and exhibiting distinctive biological and clinical features have been proposed in colorectal carcinogenesis. Methotrexate (MTX) is a potent inhibitor of the dihydrofolate reductase (DHFR) enzyme, which is essential for DNA synthesis and cell growth. We have evaluated the association between different genetic features and the capacity to develop MTX resistance in colon cancer cell lines representative of alternative genetic pathways. Three aneuploid cell lines (HT-29, SW480, and SK-CO-1) showed pre-existing amplifications, but only one (HT-29) developed MTX resistance, showing amplification of the DHFR gene at 5q12–14 (>20-fold amplification and presence of extrachromosomal double minutes). Failure to develop resistance was attributed to the absence of two complete chromosomes 5 in SW480 and SK-CO-1 cells. Four near-diploid cell lines (LoVo, HCT116, DLD-1 and KM12C) and two aneuploid KM12C-derived metastases (KM12SM and KM12L4A) developed MTX resistance but none exhibited DHFR amplification. All resistant cells without DHFR gene amplification showed microsatellite instability. We conclude that chemoresistance capacity and the mechanism of chemoresistance are related with the genetic pathway and the karyotypic features of colon cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abdel-Rahman WM, Katsura K, Rens W, Gorman PA, Sheer D, Bicknell D, Bodmer WF, Arends MJ, Wyllie AH and Edwards PA . (2001). Proc. Natl. Acad. Sci. USA, 98, 2538–2543.
Albertson DG, Collins C, McCormick F and Gray JW . (2003). Nat. Genet., 34, 369–376.
Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R and Bertino JR . (2002). Biochim. Biophys. Acta, 1587, 164–173.
Blakley RL and Sorrentino BP . (1998). Hum. Mutat., 11, 259–263.
Bosson G . (2003). Br. J. Biomed. Sci., 60, 117–129.
Camps J, Morales C, Prat E, Ribas M, Capella G, Egozcue J, Peinado MA and Miro R . (2004). Int. J. Cancer, 110, 869–874.
Chen MJ, Shimada T, Moulton AD, Cline A, Humphries RK, Maizel J and Nienhuis AW . (1984). J. Biol. Chem., 259, 3933–3943.
Chu E, Grem JL, Johnston PG and Allegra CJ . (1996). Stem Cells, 14, 41–46.
Cole PD, Kamen BA, Gorlick R, Banerjee D, Smith AK, Magill E and Bertino JR . (2001). Cancer Res., 61, 4599–4604.
Coquelle A, Pipiras E, Toledo F, Buttin G and Debatisse M . (1997). Cell, 89, 215–225.
Dicker AP, Waltham MC, Volkenandt M, Schweitzer BI, Otter GM, Schmid FA, Sirotnak FM and Bertino JR . (1993). Proc. Natl. Acad. Sci. USA, 90, 11797–11801.
Dutrillaux B . (1995). Adv. Cancer Res., 67, 59–82.
Fearon ER and Vogelstein B . (1990). Cell, 61, 759–767.
Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, Radice P, Costa A, Daidone MG, Leo E, Pilotti S, Bertario L and Pierotti MA . (2004). Clin. Cancer Res., 10, 4015–4021.
Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P and Hamelin R . (2001). Oncogene, 20, 5025–5032.
Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM and Boland CR . (2003). Cancer Res., 63, 1608–1614.
Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D and Bertino JR . (1996). N. Engl. J. Med., 335, 1041–1048.
Grady WM and Markowitz SD . (2002). Annu. Rev. Genomics Hum. Genet., 3, 101–128.
Heppner GH and Miller FR . (1998). Int. Rev. Cytol., 177, 1–56.
Leith JT and Dexter DL . (1986). Mammalian Tumor Cell Heterogeneity. CRC Press Inc.: Boca Raton, FL.
Lengauer C, Kinzler KW and Vogelstein B . (1998). Nature, 396, 643–649.
Loeb LA . (2001). Cancer Res., 61, 3230–3239.
Masramon L, Arribas R, Tortola S, Perucho M and Peinado MA . (1998). Br. J. Cancer, 77, 2349–2356.
Masramon L, Ribas M, Cifuentes P, Arribas R, Garcia F, Egozcue J, Peinado MA and Miro R . (2000). Cancer Genet. Cytogenet., 121, 17–21.
Matherly LH . (2001). Prog. Nucleic Acid Res. Mol. Biol., 67, 131–162.
Meyerhardt JA and Mayer RJ . (2005). N. Engl. J. Med., 352, 476–487.
Mitelman F, Johansson B, Mandahl N and Mertens F . (1997). Cancer Genet. Cytogenet., 95, 1–8.
Morikawa K, Walker SM, Jessup JM and Fidler IJ . (1988a). Cancer Res., 48, 1943–1948.
Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM and Fidler IJ . (1988b). Cancer Res., 48, 6863–6871.
Nunberg JH, Kaufman RJ, Schimke RT, Urlaub G and Chasin LA . (1978). Proc. Natl. Acad. Sci. USA, 75, 5553–5556.
Olschwang S, Hamelin R, Laurent-Puig P, Thuille B, De Rycke Y, Li YJ, Muzeau F, Girodet J, Salmon RJ and Thomas G . (1997). Proc. Natl. Acad. Sci. USA, 94, 12122–12127.
Perucho M, Peinado MA, Ionov Y, Casares S, Malkhosyan S and Stanbridge E . (1994). Cold Spring Harb. Symp. Quant. Biol., 59, 339–348.
Poupon MF, Smith KA, Chernova OB, Gilbert C and Stark GR . (1996). Mol. Biol. Cell, 7, 345–354.
Rajagopalan H and Lengauer C . (2004). Nature, 432, 338–341.
Ribas M, Masramon L, Aiza G, Capella G, Miro R and Peinado MA . (2003). FASEB J., 17, 289–291.
Risques RA, Moreno V, Ribas M, Marcuello E, Capella G and Peinado MA . (2003). Cancer Res., 63, 7206–7214.
Rots MG, Pieters R, Kaspers GJ, Veerman AJ, Peters GJ and Jansen G . (2000). Br. J. Haematol., 110, 791–800.
Rots MG, Pieters R, Peters GJ, Noordhuis P, van Zantwijk CH, Kaspers GJ, Hahlen K, Creutzig U, Veerman AJ and Jansen G . (1999). Blood, 93, 1677–1683.
Ruggiero T, Olivero M, Follenzi A, Naldini L, Calogero R and Di Renzo MF . (2003). Nucleic Acids Res., 31, 6561–6569.
Singer MJ, Mesner LD, Friedman CL, Trask BJ and Hamlin JL . (2000). Proc. Natl. Acad. Sci. USA, 97, 7921–7926.
Snijders AM, Fridlyand J, Mans DA, Segraves R, Jain AN, Pinkel D and Albertson DG . (2003). Oncogene, 22, 4370–4379.
Tanaka H, Tapscott SJ, Trask BJ and Yao MC . (2002). Proc. Natl. Acad. Sci. USA, 99, 8772–8777.
Tsushimi T, Noshima S, Oga A, Esato K and Sasaki K . (2001). Cancer Genet. Cytogenet., 126, 34–38.
Vogelstein B and Kinzler KW . (2004). Nat. Med., 10, 789–799.
Yunis JJ and Soreng AL . (1984). Science, 226, 1199–1204.
Acknowledgements
We thank Silvia Beà and Rosa Miró for technical support. This work was supported by a grant from the Ministry of Education and Science (SAF03/5821). C Morales is an IDIBELL fellow.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Morales, C., Ribas, M., Aiza, G. et al. Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells. Oncogene 24, 6842–6847 (2005). https://doi.org/10.1038/sj.onc.1208834
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208834
Keywords
This article is cited by
-
Tools used to assay genomic instability in cancers and cancer meiomitosis
Journal of Cell Communication and Signaling (2022)
-
Small ring has big potential: insights into extrachromosomal DNA in cancer
Cancer Cell International (2021)
-
Reversible senescence of human colon cancer cells after blockage of mitosis/cytokinesis caused by the CNF1 cyclomodulin from Escherichia coli
Scientific Reports (2018)
-
Role of Caveolin 1, E-Cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells
BMC Medical Genomics (2008)